PCA
NBSE

Peddock Capital Advisors’s NeuBase Therapeutics, Inc. Common Stock NBSE Stock Holding History

Peddock Capital Advisors’s Portfolio NBSE Stock Details NBSE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		– Sell
-1
Closed -$2K – 251
2016
Q3 		$2K Buy
+1
New +$1.08K ﹤0.01% 227

Other funds holding NBSE

SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
B
Bailard Foster City, California $4.35B AUM 23.57% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
KCM
Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
UCFA
United Capital Financial Advisors Irving, Texas $16.3B AUM 16.34% 1-Year Est. Return
California Public Employees Retirement System
California Public Employees Retirement System Sacramento, California $162B AUM 25.78% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
SIP
Stoneridge Investment Partners Radnor, Pennsylvania $138M AUM 7.66% 1-Year Est. Return

Peddock Capital Advisors's NBSE Position: Q4 2016 in Review

Peddock Capital Advisors sold out of NeuBase Therapeutics, Inc. Common Stock (NBSE) in Q4 2016, closing a stake of 1 share — an estimated $2K sold.

Peddock Capital Advisors first reported a position in NBSE in Q3 2016 and held it in 1 quarter. The position peaked at $2K in Q3 2016. 49 funds tracked by Wall St. Rank hold NBSE as of Q4 2016.

  • Peddock Capital Advisors reported no remaining NeuBase Therapeutics, Inc. Common Stock position as of Q4 2016 after selling out during the quarter.
  • Peddock Capital Advisors sold 1 NeuBase Therapeutics, Inc. Common Stock share in Q4 2016, an estimated $2K.
  • Peddock Capital Advisors first reported a position in NeuBase Therapeutics, Inc. Common Stock in Q3 2016 and held it in 1 quarter.
  • Peddock Capital Advisors's NeuBase Therapeutics, Inc. Common Stock position peaked at $2K in Q3 2016.
  • 49 funds tracked by Wall St. Rank held NeuBase Therapeutics, Inc. Common Stock as of Q4 2016.

Based on Peddock Capital Advisors's 13F filing for Q4 2016, filed 3 Feb 2017.